AbCellera Biologics Inc. (ABCL)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 17,084 | 4,235 | 6,507 | 7,323 |
| Depreciation, amortization, and impairment | - | - | 36,919 | 36,522 |
| Sales and marketing | 3,009 | 2,842 | 3,135 | 3,136 |
| Research and development | 39,213 | 42,496 | 40,969 | 40,927 |
| General and administrative | 18,977 | 16,226 | 19,147 | 20,192 |
| Depreciation, amortization, and impairment | 5,470 | 5,331 | - | - |
| Total operating expenses | 66,669 | 66,895 | 100,170 | 100,777 |
| Loss from operations | -49,585 | -62,660 | -93,663 | -93,454 |
| Other | 1,957 | -2,528 | 17,937 | 32,156 |
| Interest income | 7,592 | 8,051 | 9,603 | 9,801 |
| Grants and incentives | 3,692 | 4,153 | 3,491 | 3,310 |
| Total other income | 13,241 | 9,676 | 31,031 | 45,267 |
| Net loss before income tax | -36,344 | -52,984 | -62,632 | -48,187 |
| Income tax recovery | -1,617 | -7,363 | -11,525 | -11,257 |
| Net loss | -34,727 | -45,621 | -51,107 | -36,930 |
| Foreign currency translation adjustment | 4,341 | -2,620 | 841 | -257 |
| Comprehensive loss | -30,386 | -48,241 | -50,266 | -37,187 |
| Basic (in shares) | 298,508,601 | 297,692,663 | 294,851,945 | 294,217,013 |
| Basic (usd per share) | -0.12 | -0.15 | -0.17 | -0.13 |
| Diluted (in shares) | 298,508,601 | 297,692,663 | 294,851,945 | 294,217,013 |
| Diluted (usd per share) | -0.12 | -0.15 | -0.17 | -0.13 |